MacroGenics Announces Positive Results from Phase 3 SOPHIA Study of Margetuximab in Patients with HER2-Positive Metastatic Breast Cancer

MacroGenics Announces Positive Results from Phase 3 SOPHIA Study of Margetuximab in Patients with HER2-Positive Metastatic Breast Cancer

Annual-Meeting

7 months
38 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Scott Koenig discusses the data on the Phase 3 SOPHIA study. About MacroGenics, Inc. MacroGenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see the Company's website at www.macrogenics.com. MacroGenics and the MacroGenics logo are trademarks or registered trademarks of MacroGenics, Inc.
Up Next Autoplay
EZH2 in Triple Negative Breast Cancer: What's Next in Research? @Ramon_Parsons @IcahnMountSinai
EZH2 in Triple Negative Breast Cancer: What's Next in Research? @Ramon_Parsons @IcahnMountSinai
Category: Breast Cancer
2 Views
Mount Sinai Health System 1 week
EZH2 in Triple Negative Breast Cancer @Ramon_Parsons @IcahnMountSinai
EZH2 in Triple Negative Breast Cancer @Ramon_Parsons @IcahnMountSinai
Category: Breast Cancer
1 Views
Mount Sinai Health System 1 week
SOHPIA Study in Metastatic Breast Cancer #SABCS19 @UCSFMedicine
SOHPIA Study in Metastatic Breast Cancer #SABCS19 @UCSFMedicine
Category: Breast Cancer
31 Views
ash 3 weeks
MacroGenics Presents Results from the SOPHIA Study of Margetuximab in Patients with HER2-Positive Metastatic Breast Cancer at the San Antonio Breast Cancer Symposium
MacroGenics Presents Results from the SOPHIA Study of Margetuximab in Patients with HER2-Positive Metastatic Breast Cancer at the San Antonio Breast Cancer Symposium
Category: Breast Cancer
17 Views
Cancer-News 3 weeks
Prognostic Marker in Operable Breast Cancer: How This Affects Clinicians? #SABCS19
Prognostic Marker in Operable Breast Cancer: How This Affects Clinicians? #SABCS19
Category: Breast Cancer
6 Views
ash 3 weeks
Prognostic Marker in Operable Breast Cancer #SABCS19
Prognostic Marker in Operable Breast Cancer #SABCS19
Category: Breast Cancer
22 Views
admin 3 weeks
The FLEX Real World Data #SABCS19 @BaptistHealthSA
The FLEX Real World Data #SABCS19 @BaptistHealthSA
Category: Breast Cancer
26 Views
admin 3 weeks
Agendia Presents New Data at #SABCS19 in Breast Cancer
Agendia Presents New Data at #SABCS19 in Breast Cancer
Category: Breast Cancer
7 Views
admin 3 weeks
New Evidence from Large Studies Highlights Value of Oncotype DX Breast Recurrence Score® to Guide Chemotherapy Treatment in Young Patients with Node-negative or Node-positive Early-stage...
New Evidence from Large Studies Highlights Value of Oncotype DX Breast Recurrence Score® to Guide Chemotherapy Treatment in Young Patients with Node-negative or Node-positive Early-stage...
Category: Breast Cancer
12 Views
Cancer-News 1 month
Novartis Kisqali® data show superior overall survival compared to fulvestrant and consistent efficacy across advanced breast cancer patient subgroups in MONALEESA-3
Novartis Kisqali® data show superior overall survival compared to fulvestrant and consistent efficacy across advanced breast cancer patient subgroups in MONALEESA-3
Category: Breast Cancer
18 Views
cancernewsupdate 1 month